Use of p62/SQSTM1 antibodies for neuropathological diagnosis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The demonstration of proteinaceous inclusions in the brain is the key step in the pathological diagnosis of degenerative dementias. The diversity of these diseases has necessitated the use of a panel of (immuno)stains to visualize all suspect pathologies, elevating diagnostic costs. Immunodetection of p62 (sequestosome 1), an abundant constituent in diverse pathological inclusions, holds the potential for a broad‐specificity, high‐contrast inclusion label. In the brain, pathological p62‐positive aggregates comprise both cytoplasmic and nuclear types in neurones and glia, with abnormal tau, alpha‐synuclein, TAR DNA‐binding protein 43 or polyglutamine proteins as primary components. We therefore set out to evaluate the performance of p62 antibodies for diagnostic immunohistochemistry. We optimized the application conditions and compared the staining profiles of eight commercial p62 antibodies with each other and with reference immunostains, using 2‐mm tissue multiarrays representing the major tauo‐ and synucleinopathies and frontotemporal lobar degeneration with ubiquitin‐positive inclusions (FTLD‐U). The lesions were best visualized using monoclonal antibodies, displaying most types of hallmark inclusions with excellent contrast. Expanding the list of p62‐containing aggregates, we demonstrated p62 in tufted astrocytes, coiled bodies, astrocytic plaques, and variform neocortical inclusions and pathological processes in FTLD‐U. Polyclonal antibodies exhibited lower sensitivities with variable background levels. We also noted more subtle p62‐immunoreactive features lacking overt disease associations. Emphasizing the importance of proper antibody and epitope unmasking methods for maximum sensitivity, we recommend p62 immunodetection as a screening stain for diagnostic practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H., & Johansen, T. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200507002 · Cited by 3,276
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62
Rodriguez, A., Durán, A., Selloum, M., Champy, M.-F., Diez-Guerra, F. J., Flores, J. M., Serrano, M., Auwerx, J., Diaz-Meco, M. T., & Moscat, J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.011 · Cited by 290
Alafuzoff, I., Pikkarainen, M., Al-Sarraj, S., Arzberger, T., Bell, J., Bodi, I., Bogdanovic, N., Budka, H., Bugiani, O., Ferrer, I., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000229986.17548.27 · Cited by 117
Self-citationArai, T., Nonaka, T., Hasegawa, M., Akiyama, H., Yoshida, M., Hashizume, Y., Tsuchiya, K., Oda, T., & Ikeda, K. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00216-7 · Cited by 92
SQSTM1 and Paget?s Disease of Bone
Layfield, R., & Hocking, L. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0041-0 · Cited by 76
Cited by
Selective autophagy mediated by autophagic adapter proteins
Johansen, T., & Lamark, T. (2011) · Autophagy · doi:10.4161/auto.7.3.14487 · Cited by 1,730
Chapter 12 Monitoring Autophagic Degradation of p62/SQSTM1
Bjørkøy, G., Lamark, T., Pankiv, S., Øvervatn, A., Brech, A., & Johansen, T. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(08)03612-4 · Cited by 1,069
Invited review: Neuropathology of tauopathies: principles and practice
Kovacs, G. G. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12208 · Cited by 492
Clinicopathological features of adult-onset neuronal intranuclear inclusion disease
Sone, J., Mori, K., Inagaki, T., Katsumata, R., Takagi, S., Yokoi, S., Araki, K., Kato, T., Nakamura, T., Koike, H., et al. (2016) · Brain · doi:10.1093/brain/aww249 · Cited by 416
Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration
Golestaneh, N., Chu, Y., Xiao, Y.-Y., Stoleru, G. L., & Theos, A. C. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.453 · Cited by 357
“nated protein aggregates in various neurodegenerative diseases.(39) As p62 degradation depends on autophagy, the level of p62 protein is another indicator of autophagic flux.”
Metadata
- Authors
- Kuusisto, E., Kauppinen, T., & Alafuzoff, I.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2007-10-31
- Volume
- 34
- Issue
- 2
- Pages
- 169-180
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- OpenAlex
- W1982916090
- Cited by
- 113
- References
- 6
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of p62/SQSTM1 antibodies for neuropathological diagnosis. https://app.cochat.ai/papers/10.1111/j.1365-2990.2007.00884.x
- The paper
- Kuusisto, E., Kauppinen, T., & Alafuzoff, I. (2008). Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/j.1365-2990.2007.00884.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.